News

Patients, caregivers, family members, and friends are set to mark Pulmonary Hypertension Awareness Month, observed each November to call attention to the complex, chronic, progressive disorder. Awareness and education are vital to heightening the recognition, diagnosis, understanding, and management of pulmonary hypertension (PH), a disease associated with high blood…

Children with episodes of fainting due to pulmonary arterial hypertension (PAH) who respond well to a vasodilator given in a challenge test are likely to have better long-term outcomes than those who respond poorly, a long-term records study suggests. A vasodilator challenge is a test to measure blood pressure in…

Premature newborns who are treated for eye problems with anti-VEGF therapies may be at increased risk of developing pulmonary hypertension, a new study suggests. “Future studies evaluating the safety of anti-VEGF therapy should include pulmonary hypertension as a key clinical outcome. This is especially important as anti-VEGF treatment usage…

The U.S. Food and Drug Administration (FDA) granted breakthrough device designation to the CorVista System, a point-of-care diagnostic tool that aims to use non-invasive tests and machine learning to help diagnose pulmonary hypertension and other cardiovascular disorders. The designation gives CorVista Health, the system’s developer, certain benefits aimed…

People with pulmonary arterial hypertension (PAH) are at a higher risk of acute heart failure when admitted to the hospital for sepsis or septic shock than are patients without PAH, a U.S. study found. Sepsis — the body’s severe response to infection — in PAH patients, however, was not…

Treatment with Adcirca (tadalafil) or Revatio (sildenafil) may help patients who develop pulmonary hypertension secondary to an interstitial lung disease to live longer, according to a new study from the U.K. “Patients treated with [these therapies] survived longer than untreated patients,” the researchers wrote, noting a median survival of…

Pulmonary hypertension (PH) is linked with changes in the gut microbiome — the vast community of bacteria, fungi, and viruses that colonize the gastrointestinal tract — and an imbalance in protective versus disease-related metabolites, or molecules that take part in metabolism, according to a rat model of the disease.

Despite treatment advances in pulmonary hypertension (PH) over the last two decades, the age-adjusted PH-related death rate in the U.S. increased annually between 1999 and 2019, with mortality climbing by nearly 2% each year, a new study found. The simultaneous presence of PH and disease of the left side…

Switching from weekly infusions of levosimendan to a daily oral version of the experimental medication was well-tolerated among people with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), according to new trial data. That data, from the open-label extension phase of the HELP Phase 2 clinical…

Treatment with sotatercept, given in addition to standard therapies, significantly improves exercise capacity in people with pulmonary arterial hypertension (PAH). Those are the new findings of a pivotal Phase 3 clinical trial called STELLAR, which tested the therapy’s safety and efficacy in improving PAH patients’ ability to walk. Now,…

Less oxygen uptake during exercise increases the risk of clinical worsening in people with pulmonary hypertension (PH) due to a heart defect called pulmonary artery stenosis (PAS), a study shows. Data also showed the chance of recovery was generally poor for this subgroup of patients and it was common…

Two weeks of aerobic exercise improved blood flow parameters and survival in a rat model of pulmonary arterial hypertension (PAH), and altered the energy usage of cells in the heart, a new study reports. “Our data support the beneficial effect of exercise training in this clinical setting, as two…